Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Mechanistic insight into the activity of a sulfone compound dapsone on Propionibacterium (Newly Reclassified as Cutibacterium) Acnes-mediated cytokine production.

Geyfman M, Debabov D, Poloso N, Alvandi N.

Exp Dermatol. 2019 Feb;28(2):190-197. doi: 10.1111/exd.13869.

PMID:
30585659
2.

Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials

Stein-Gold L, Kircik L, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg D, Kaufman J, Tanghetti E, Ahluwalia G, Alvandi N, Weng E, Berk D.

J Drugs Dermatol. 2018 Nov 1;17(11):1201-1208.

PMID:
30500142
3.

Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females

Tanghetti E, Harper J, Baldwin H, Kircik L, Bai Z, Alvandi N.

J Drugs Dermatol. 2018 Nov 1;17(11):1192-1198.

PMID:
30500141
4.

Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females

Tanghetti E, Harper J, Baldwin H, Kircik L, Bai Z, Alvandi N.

J Drugs Dermatol. 2018 Nov 1;17(11):1192-1198.

PMID:
30500140
5.

Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females

Tanghetti E, Harper J, Baldwin H, Kircik L, Bai Z, Alvandi N.

J Drugs Dermatol. 2018 Nov 1;17(11):1192-1198.

PMID:
30500139
6.

Use of an Alternative Method to Evaluate Erythema Severity in a Clinical Trial: Difference in Vehicle Response With Evaluation of Baseline and Postdose Photographs for Effect of Oxymetazoline Cream 1.0% for Persistent Erythema of Rosacea in a Phase 4 Study.

Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N.

Br J Dermatol. 2018 Nov 30. doi: 10.1111/bjd.17462. [Epub ahead of print]

PMID:
30500065
7.

Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.

Zhanel G, Critchley I, Lin LY, Alvandi N.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. doi: 10.1128/AAC.01297-18. Print 2019 Jan.

8.

Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.

Tanghetti EA, Dover JS, Goldberg DJ, Dhawan SS, Luo L, Berk DR, Ahluwalia G, Alvandi N.

J Drugs Dermatol. 2018 Jun 1;17(6):621-626.

PMID:
29879249
9.

Clinical Experience With Once-Daily Dapsone Gel, 7.5% Monotherapy in Patients With Acne Vulgaris.

Stockton TC, Tanghetti EA, Lain E, Zeichner JA, Alvandi N.

J Drugs Dermatol. 2018 Jun 1;17(6):602-608.

PMID:
29879247
10.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.

Gold MH, Lebwohl M, Biesman BS, Robinson DM, Luo L, Berk DR, Ahluwalia G, Alvandi N.

J Am Acad Dermatol. 2018 Sep;79(3):e57-e59. doi: 10.1016/j.jaad.2018.05.037. Epub 2018 May 31. No abstract available.

PMID:
29860043
11.

Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.

Taylor SC, Cook-Bolden FE, McMichael A, Downie JB, Rodriguez DA, Alexis AF, Callender VD, Alvandi N.

J Drugs Dermatol. 2018 Feb 1;17(2):160-167.

PMID:
29462223
12.

Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings.

Kennelly M, Green L, Alvandi N, Wehbe S, Smith JJ 3rd, MacDiarmid S, Mangel J, Schwartz M, Aboushwareb T, Murray B.

Curr Med Res Opin. 2018 Oct;34(10):1771-1776. doi: 10.1080/03007995.2018.1443061. Epub 2018 Mar 20.

PMID:
29458265
13.

WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.

Stein-Gold L, Kircik LH, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg DJ, Kaufman J, Tanghetti EA, Alvandi N, Weng E, Berk DR, Ahluwalia G.

J Am Acad Dermatol. 2018 Jan 31. pii: S0190-9622(18)30147-6. doi: 10.1016/j.jaad.2018.01.028. [Epub ahead of print] Erratum in: J Am Acad Dermatol. 2018 Apr 12;:.

14.

Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.

Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G.

J Am Acad Dermatol. 2018 Jun;78(6):1156-1163. doi: 10.1016/j.jaad.2018.01.027. Epub 2018 Jan 31.

Supplemental Content

Loading ...
Support Center